Objective Hypertensive disorders in pregnancy signal an increased risk of cardiovascular disease for women. However, future hypertension risk among pregnant women with moderately elevated blood pressure (BP) is unknown. We examined associations among moderately elevated BP or hypertensive disorders during pregnancy and later prehypertension or hypertension.
Introduction
Hypertension (HTN), defined as systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg, is prevalent among 30% of the adult population in the USA and England. 1, 2 HTN is an established risk factor for subsequent cardiovascular and renal diseases, and contributes to more cardiovascular (CVD) events in women than men. 3, 4 In addition, prehypertension (preHTN), defined as SBP of 120-139 mmHg and/or DBP of 80-89 mmHg, is a recognised risk factor for subsequent CVD. [5] [6] [7] [8] [9] Normal pregnancy may be a 'stress test' for the mother, bringing with it numerous physiological changes including increased cardiac output and blood volume with blood pressure (BP) changes. 10 BP remains at approximately the same level from pre-pregnancy through to the end of the first trimester, after which it drops. [10] [11] [12] It increases again in the latter part of the second trimester and continues to increase until the birth. Pregnancy-onset hypertension and *GL Dunietz and KL Strutz contributed equally as first author.
pre-eclampsia are characterised by BP ≥ 140 mmHg systolic or 90 mmHg diastolic on two occasions after 20 weeks of gestation, with pre-eclampsia also including presence of proteinuria, or severe features. 13, 14 Chronic hypertension is diagnosed as BP ≥ 140 mmHg systolic or 90 mmHg diastolic before pregnancy or before 20 weeks of gestation with failure to resolve postpartum.
14 Prevalence of these disorders, collectively known as hypertensive disorders of pregnancy (HDP), ranges from 5% to 10%. 15 However, there are no existing criteria for preHTN during pregnancy and the long-term maternal risks associated with moderate BP elevation are unknown.
In addition to their association with adverse birth outcomes, HDP also carry long-term risks for HTN and CVD. 16, 17 HDP have been consistently associated with increased risk of future HTN and CVD-related mortality. [18] [19] [20] It is not known whether the risk of later-life HTN is also increased by moderately elevated BP that does not meet the diagnostic criteria for a hypertensive disorder. Therefore, our objective was to investigate the risk of later preHTN and HTN among women with moderately elevated BP in pregnancy in addition to those diagnosed with HDP. Further, we examined whether type (i.e. elevated systolic, diastolic or both) and timing of moderately elevated BP were differentially associated with later HTN status.
Methods

Study design and analytic sample
We used data from the subcohort of the Pregnancy Outcomes and Community Health (POUCH) Study. 21 A flowchart of study participants for the current analyses is shown in Figure 1 . Designed to examine pathways leading to preterm delivery, the initial POUCH Study enrolled 3019 pregnant women from 1998 to 2004 receiving prenatal care from 52 clinics in five Michigan communities. Inclusion criteria were maternal age of at least 15 years, singleton pregnancies with no known congenital anomalies, a prenatal maternal serum a-fetoprotein (a-FP) measure between 15 and 22 weeks of gestation, no diabetes mellitus, and competency in English. A subcohort of 1371 participants was created to collect more detailed information and biological samples. This subcohort included all those delivering preterm (<37 weeks of gestation) or with elevated maternal serum a-FP (>2 multiples of the median), and a random sample of those delivering at term with normal maternal serum a-FP in which African-American participants were oversampled. In all analyses sampling weights are used to account for the cohort and subcohort sampling strategy. Detailed investigations of biological samples collected at mid-pregnancy and delivery and medical record abstractions were conducted for the subcohort only, and these women were the focus of follow-up studies. POUCHmoms, the most recent follow-up study of the subcohort, was designed to examine early evidence of CVD 7-15 years after the POUCH Study pregnancy; we hypothesised that pregnancy complications reveal underlying predispositions to CVD. The POUCHmoms follow-up included an in-person interview along with measures of blood pressure, heart rate variability, anthropometrics, carotid ultrasound scans and collection of fasting blood samples for atherogenic biomarkers. A total of 678 participants from the original subcohort completed this protocol from 2011 to 2014. Our analytical sample excluded 11 POUCHmoms Study participants who were missing BP measurements during pregnancy. Study procedures were undertaken with the understanding and appropriate informed consent of each participant.
Measures
Hypertensive status in pregnancy Eight BP measurements during the POUCH Study pregnancy, along with the measurement dates, were abstracted from the medical record and used for this analysis. These were the two highest SBP recorded before 20 weeks of gestation, the two highest DBP recorded before 20 weeks of gestation, the two highest SBP recorded at or after 20 weeks of gestation and the two highest DBP recorded at or after 20 weeks of gestation.
We categorised a participant as having moderately elevated BP if at least two of her highest SBP readings were ≥ 120 mmHg or at least two of her highest DBP readings were ≥ 80 mmHg and she did not have HDP (described below). The moderately elevated BP group was further subdivided by whether the elevation was in SBP only, DBP only, or both. There were only two participants with elevated DBP and normal SBP, so this group was too small to analyse separately. These women were removed from analyses subdivided by type of elevation. In addition, the moderately elevated BP group was subdivided by gestational week when moderately elevated BP was first identified, i.e. <20 weeks, ≥ 20 weeks of gestation. Approximately 26% of the total moderately elevated BP group had one (but not two) BP measure of ≥ 140 mmHg SBP or ≥90 mmHg DBP and did not meet the definition of HDP.
Hypertensive disorder information was derived from medical chart reviews. For these analyses, participants were categorised with HDP if they were explicitly diagnosed with any hypertensive disorder (pre-eclampsia/eclampsia, pregnancyinduced hypertension, chronic hypertension) or met the criteria for any of these disorders on two separate calendar days. Pre-eclampsia and pregnancy-induced hypertension were defined as ≥ 140 mmHg SBP or ≥ 90 mmHg DBP on two occasions after 20 weeks of gestation, with pre-eclampsia requiring presence of proteinuria. Chronic hypertension was defined as ≥ 140 mmHg SBP or ≥ 90 mmHg DBO before pregnancy or before 20 weeks of gestation on two separate occasions. Women who did not have HDP or chronic hypertension and did not meet our criteria for moderately elevated BP were classified as normotensive (referent group).
Participants with a history of hypertensive medication use were classified with chronic hypertension. All models were rerun with chronic hypertensive participants (n = 26) removed from the HDP group. The results did not differ, so the chronic hypertensive participants were retained in the final sample.
Hypertensive status and BP at follow-up As recommended in the Joint National Committee (JNC7) guidelines, 5 three consecutive BP measurements were made, 1 minute apart, at the POUCHmoms Study visit. Trained research assistants, who were registered nurses or ultrasonographers with experience in BP measurement, measured BP seated with the arm extended level to the heart, using either a Panasonic EW3109W (Panasonic Corp., Newark, NJ, USA) or an Omron Hem-907 (Omron Healthcare, Inc., Lake Forest, IL, USA) monitor with a small, medium or large cuff as appropriate. Both digital monitors were compared with manual readings and with each other before data collection to ensure that readings were comparable. We averaged the second and third of these blood pressure recordings for our measure. We categorised hypertensive status at the POUCHmoms Study follow-up according to the JNC criteria. Hence, participants with SBP <120 mmHg and DBP <80 mmHg were classified as normotensive, those with SBP between 120 and 139 mmHg or with DBP between 80 and 89 mmHg were classified with preHTN, and those with SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or using antihypertensive medications were classified with HTN.
Covariates
Potential confounders were variables known to be associated with HTN during and/or after pregnancy. These included race/ethnicity (dichotomised as African-American versus white or other), pre-pregnancy body mass index (BMI; defined as weight in kilograms divided by the square of height in metres and modelled as continuous), age (continuous) and parity (categorised as 0, 1 or 2+) at the time of the POUCH Study pregnancy, Medicaid insurance coverage at the time of the POUCH Study pregnancy as an indicator of socio-economic status (dichotomised as yes or no), and the time between the POUCH Study pregnancy and follow-up (continuous, in years). Race/ethnicity, prepregnancy BMI and Medicaid status were also tested as potential effect modifiers. BMI at follow-up (continuous) was evaluated as a potential intermediary variable or effect modifier.
Statistical analyses
We used univariate and bivariate descriptive statistics to examine variable distributions overall and across categories of hypertensive status during pregnancy and follow-up. Differences by hypertensive status were assessed with Chisquare tests; P < 0.05 was considered statistically significant. Multinomial logistic regression models produced crude and adjusted odds ratios (ORs) with 95% confidence intervals (95% CIs) for preHTN and HTN at follow-up for each prenatal BP category, with normotensive as the referent category at both time-points. Differences among the prenatal BP categories were tested with contrast statements. These models were run with and without BMI at followup, and were repeated by type and timing of moderately elevated BP. Effect modification was tested with interaction terms; none was significant and therefore they were excluded from the final models.
All analyses were run with the survey procedures in SAS v9.3 (SAS Institute Inc., Cary, NC, USA) to incorporate the original POUCH Study sampling design and weighting. These weights accounted for the oversampling of participants delivering preterm, with elevated maternal serum a-FP and of African-American race. For example, in the POUCHmoms Study follow-up analyses, each woman remained in her POUCH Study stratum (e.g. white non-Hispanic, normal maternal serum a-FP, preterm) for the purpose of calculating sampling weights, thereby maintaining the appropriate proportionality (from the original population) of each stratum to the total follow-up sample (denominator of 667 for these analyses). The weights were not altered to account for lossto-follow-up in the POUCHmoms Study. However, a sensitivity analysis was conducted with the unweighted data to determine whether conclusions would differ between weighted and unweighted analyses.
Results
Characteristics of the analytical sample are compared with those of the remaining POUCH Study subcohort participants in the Supplementary material (Table S1 ). The women in the follow-up sample were more highly educated, less likely to have received Medicaid insurance at pregnancy, more likely to be of white or other race/ethnicity, and more likely to have come from the Lansing community. However, pre-pregnancy BMI, preterm delivery, delivery of a small-for-gestational-age infant, and prenatal BP categories did not differ between women in the followup study and those not followed.
Maternal and pregnancy characteristics by HTN status at follow-up are displayed in Table 1 . White/other women were more likely to be classified as normotensive at followup compared with African-American women (60% versus 44%). Mean BMI, both pre-pregnancy and at follow-up, and mean maternal age at both enrolment and follow-up displayed positive linear associations with HTN status at follow-up, although age at enrolment was only borderline (Table S2) . Multinomial logistic regression results are shown in Table 2 . Women with moderately elevated BP in pregnancy *Coefficients are based on weighted data. **Adjusted for race/ethnicity; pre-pregnancy BMI; age, parity, and Medicaid at pregnancy; and interval between birth and follow-up. ***Adjusted for all covariates listed above plus BMI at follow-up. ****n = 665 for these models, which exclude those with moderately elevated diastolic BP only (n = 2).
had significantly increased odds of HTN at follow-up in the crude model (Section A, Model 1: OR 2.4, 95% CI 1.3-4.6) and the model adjusted for pregnancy confounders (Model 2: OR 2.6, 95% CI 1.2-5.5) ( Table 2) . Adding BMI at follow-up to the adjusted model attenuated the OR slightly (Model 3: OR 2.3, 95% CI 1.0-5.1). Moderately elevated BP in pregnancy was not associated with followup preHTN in any models. As expected, HDP were positively associated with later preHTN and HTN; again BMI at follow-up modestly attenuated the effect estimates (Model 3: preHTN OR 2.5, 95% CI 0.9-6.6; HTN OR 13.7, 95% CI 4.4-42.9).
Results with moderately elevated BP in pregnancy divided by type and timing are shown in Table 2 , Sections B and C, respectively. Moderately elevated SBP in pregnancy, alone and in combination with elevated DBP, significantly increased the odds of HTN at follow-up in most models ( Table 2 , Section B). Early moderately elevated BP (<20 weeks of gestation) significantly increased the odds of HTN three-to four-fold at follow-up in all models (Table 2 , Section C). Late moderately elevated BP (≥ 20 weeks of gestation) was not statistically significantly associated with HTN at follow-up after controlling for BMI at follow-up, although it led to approximately double the odds of HTN in all models. The odds ratios for HTN at follow-up for early moderately elevated BP were significantly higher than those for later moderately elevated BP (P < 0.05). The sensitivity analysis repeating all models with unweighted data produced similar results (see Table S3 ).
Discussion
Main findings
This prospective study followed pregnant women to examine their health status 7-15 years later. We found that moderately elevated BP in pregnancy is significantly associated with approximately twice the odds of future HTN. This is true whether SBP is elevated alone or in conjunction with elevated DBP. The observed association between moderately elevated BP and future HTN is larger when BP is elevated before 20 weeks of gestation, the gestational cutoff used for distinguishing chronic, pre-existing HTN from pregnancy-induced HTN, 13, 14 but is also seen when BP is elevated later.
Strengths and limitations
One limitation of this work is the differences in some characteristics between the POUCH Study subcohort participants followed versus those not followed that could potentially lead to selection bias. However, it was reassuring that these differences did not occur based on pregnancy outcome (term versus preterm, small-for-gestational-age) or on BP. In addition, the potential follow-up biases present (e.g. maternal education, Medicaid) applied equally to each of the sampling strata; therefore, our approach to using the original POUCH Study strata for calculating sampling weights did not appear to introduce additional follow-up bias. Instead, our weighting by race/ethnicityspecific strata helped to account for some of the differential in follow-up by race/ethnicity.
Additional limitations include that we were able to assess moderately elevated BP only in the POUCH Study pregnancies, without knowledge of whether it occurred in previous or later pregnancies as well. It is plausible that recurring moderately elevated BP is more indicative of later HTN risk; research in other cohorts will be necessary to test this hypothesis. We did not have measurements of pre-pregnancy BP to establish whether any participants had preHTN before pregnancy. However, it is worth noting that many women of reproductive age do not know this information themselves before entering prenatal care. Furthermore, our BP measurements in pregnancy were part of the participants' clinical care rather than standardised by a study protocol, and not all BP measurements were abstracted for the POUCH Study. Our follow-up BP categories were based on BP measured at one study visit; repeated BP measures over time might remove some intra-individual variability and provide more precise confidence limits.
Finally, given the age range of the participants at followup, our study was limited to examining early development of HTN and could not assess CVD-related events. However, the associations seen here between moderately elevated BP during pregnancy and HTN in young and middle-aged adults confirm the potential for identifying at-risk women earlier in their lives. Our follow-up period of 7-15 years is comparable to those of studies showing progression of preHTN to CVD outcomes in the general population. [6] [7] [8] [9] Despite these limitations, our study has several strengths. First, to our knowledge, it is the first to apply the preHTN criteria to a pregnant population to assess odds of later HTN. Second, the population represents a socio-economically diverse community-based sample followed longitudinally. Third, both the POUCH Study and its POUCHmoms follow-up contain rich measures, including objective BP measurements that allow for deeper investigation of the mechanisms underlying the phenomena reported here.
Interpretation
Although our results confirm previous reports outside pregnancy that elevated BP is associated with later life HTN, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] our study is novel, as it applies the preHTN criteria used in the general population to pregnancy. Our findings extend studies of preHTN in the general population that demonstrate the importance of elevated SBP in progressing to HTN. 23, 24 It had previously been assumed that only moderate to severe HDP presented a concern for maternal and infant health. 29 However, emerging evidence suggests that elevated BP among pregnant women without HDP is associated with increased risk of poor offspring health outcomes including fetal growth restriction and preterm delivery. [32] [33] [34] [35] Our study extends these findings to an adverse maternal health outcome in later life.
Our data showing a stronger association between later HTN and moderately elevated BP before 20 weeks of gestation points to the first half of pregnancy as particularly revealing because it detects women with previously undiagnosed preHTN, and/or women who do not show the typical lowering of BP in response to pregnancy-related physiological changes arising during these gestational weeks. Women in our sample with moderately elevated BP only after 20 weeks of gestation also had higher odds of HTN at follow-up, although the effect size was smaller. Women with later moderately elevated BP onset offer further evidence that pregnancy may unmask an increased risk of HTN in affected women who enter pregnancy with normotensive BP. Future research will be needed to shed greater light on these critical windows.
Given the physiological changes of pregnancy, it is not surprising that moderately elevated BP is highly prevalent in pregnancy when moderately elevated BP is defined by prehypertensive cut-offs used for nonpregnant populations. Our finding that 64% of women had moderately elevated BP in pregnancy suggests that our definition, parallel to the JNC7 definition of preHTN, 5 has high sensitivity but low specificity for predicting later HTN. It is surprising that there is no association between moderately elevated BP in pregnancy and later preHTN, given that preHTN is often on the pathway to hypertension. This null finding may reflect that moderately elevated BP is not a constant state, and repeated measures are needed to better identify women who truly belong in this category.
Conclusion
In conclusion, we identified a significant association between moderately elevated BP in pregnancy and later HTN. This approach parallels that of the increasing recognition that pregnancy factors such as gestational weight gain have immediate consequences for perinatal outcomes as well as long-term impacts on maternal metabolic and cardiovascular health. 36 In future work, we will focus on further improving the prediction of later life HTN by considering gestational BP measurements alongside other biomarkers measured in pregnancy. Given that pregnancy represents a time of frequent contact between women and the healthcare system, our findings for moderately elevated BP suggest that prenatal care may be an effective time to identify women at risk of later HTN beyond identifying women with hypertensive disorders of pregnancy. Closer monitoring of women with gestational moderately elevated BP coupled with timely intervention may help to curtail the incidence of CVD among at-risk women.
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